NYALA Digital Asset AG paves new way for digital securities as a profitable investment
FRANKFURT, Germany, May 29, 2025 /PRNewswire/ -- The financial world is undergoing a revolutionary transformation, and NYALA Digital Asset AG is positioning itself as a pioneer in this change. This German company is shaping the future of capital markets and opening new paths for businesses and investors alike.
NYALA is the first truly digital alternative to traditional investment banks. The company offers a platform through which stocks and bonds can be issued—without exchanges, banks, or paperwork. Faster, cheaper, and across borders. In doing so, NYALA is democratizing both capital access for companies and investment opportunities for retail investors.
NYALA's pioneering work is regulated under Germany's Electronic Securities Act (eWpG) and was recently awarded a government research grant from the German Federal Ministry of Research.
NYALA solves a serious issue: traditional capital markets aren't built for small and mid-sized enterprises. IPOs require multi-million budgets and specialized legal advisors. As a result, 90% of mid-sized growth companies lack access. This often leads to the most exciting investment opportunities being allocated behind closed doors—to exclusive investor circles.
A New Era for Capital Markets: DPO Instead of IPO
What used to be a costly and complex IPO is now a lean, digital process. NYALA enables so-called DPOs—Digital Public Offerings. Companies issue securities directly to investors via digital channels: through their websites, apps, or partner platforms.
According to Larry Fink, CEO of BlackRock—the world's largest asset manager—the future of capital markets lies in this kind of digital securities. The market holds enormous potential: by 2030, volumes of over €10 trillion are expected. In Europe, there is an annual funding gap of €800 billion that NYALA aims to close. Already, over 5,000 investors and issuers from six EU countries trust the platform.
An Exciting Announcement for Investors:
With a current share price of around €90, significant short-term potential and a target above €1.000, investors can now participate online—a process as simple as online shopping. And 15% of investments in NYALA can be refunded by the German Office for Economic Affairs. More information at https://digital.nyala.de.
Against this backdrop, the business editors of the FRANKFURTER TAGESZEITUNG see NYALA as one of the pioneers in the digital transformation of the financial sector. NYALA is now expanding across Europe and offers investors the chance to get in early on a promising future. With a solid foundation and a clear growth path, this Berlin-based company is revolutionizing how capital is raised and applied to benefit the European economy. The digitization of finance has begun—and NYALA is leading it forward.
META DESCRIPTION:
Discover NYALA Digital Asset AG: Digital securities are revolutionizing the capital market. Yield-driven investments for private investors and new financing routes for SMEs. Join the funding round now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
33 minutes ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
Korea Herald
an hour ago
- Korea Herald
Trump's 50% steel tariff deals blow to Korean exporters
New US levy threatens 13% of Korea's steel exports, prompting emergency talks in Seoul In yet another tariff storm last week, US President Donald Trump shocked the world once more with plans to double tariffs on imported steel and aluminum from 25 percent to 50 percent, starting Wednesday. Speaking from a US Steel mill in the Pittsburgh suburbs, Trump described the move as a deal that would 'secure' the American steel industry, one that 'nobody's going to get around.' The tariff escalation is set to deliver another major blow to Korean exporters, the fourth-largest steel supplier to the US. In 2024, exports to the US accounted for 13 percent of Korea's total steel exports. 'At a time when exports to the US are barely holding up following the 25 percent tariff, an additional 25 percent will severely undermine the competitiveness of Korean companies,' said an industry insider. In response, Korean trade officials and steelmakers, including Posco Holdings and Hyundai Steel, gathered Monday for an emergency meeting convened by the Ministry of Trade, Industry and Energy in Seoul to assess the fallout. The agenda centered on evaluating the potential impact of the tariff hike on the industry and formulating future response strategies. While closely monitoring the situation through its networks with US diplomatic offices and the US subsidiaries of Korean companies, the ministry has pledged to implement swift responses to 'minimize' the impact on Korea's steel sector. Some analysts, however, suggest the damage may be limited. According to a Seoul-based market researcher at Daol Investment & Securities, even after the initial 25 percent tariff, US prices for hot-rolled steel remained high. 'The full impact of the new hike depends on how much US steel prices rise in response,' the researcher said. That, in turn, may increase the competitive edge of companies like Hyundai Steel. The company is committed to a $5.8 billion investment plan to build an electric arc furnace-based integrated steel mill in Louisiana by 2029, in partnership with Posco Group. The tariff hike comes amid the US push to bolster its domestic steel industry, which constitutes the backbone of the nation, according to Trump. Trump recently endorsed US Steel's $14 billion acquisition by Japan-based Nippon Steel, a deal he had previously opposed on national security grounds. He said the partnership would create and save more than 100,000 jobs while keeping the American steelmaker under US control, though few details have been disclosed. Although the Court of International Trade ruled last week against Trump's tariffs under the International Emergency Economic Powers Act, potentially hindering his use of punitive levies, it has no bearing on steel and aluminum tariffs. Those instead fall under Section 232 of the Trade Expansion Act, which authorizes tariffs on national security grounds.
Korea Herald
21 hours ago
- Korea Herald
Tianfu Rapoil Shines at Hong Kong Hometown Market Carnival
HONG KONG, June 1, 2025 /PRNewswire/ -- This is a report from Xinhuanet: Co-organized by 30 provincial-level hometown associations in Hong Kong, the "Third Hometown Market Carnival" was kicked off on June 1 in Victoria Park, marking the beginning of the five-day event. The Sichuan Provincial Grain and Material Reserve Bureau showcased its premium products under the 'Tianfu Rapoil' brand at the event, becoming the star attraction in this year. At the event, Tianfu Rapoil brought nearly 2,000 products, ranging from 'Traditional Small-Pressed Rich-Aromatic Rapeseed Oil' made using non-heritage pressing techniques, to low-erucic acid rapeseed oil, and small-packaged rapeseed oil specifically designed for younger consumers. On-site, residents and tourists participated in 'Come to Play and Win Oil in Victoria Park'. They not only won Tianfu Rapoil products but also received its limited-edition cultural and creative merchandise. Items such as umbrellas, folding fans, and canvas bags featuring panda patterns became the most sought-after items at the event. This year's Hong Kong Hometown Market Carnival features a special Chinese Food Street, with 30 food stalls offering cuisines from all over China. When Tianfu Rapoil meets regional specialities such as Xinjiang lamb skewers, Shaanxi Roujiamo, and Hunan Changde rice noodles, magical sparks occur. At Xinjiang association stall, chefs blended Tianfu rapeseed oil with cumin and chili powder to create a secret sauce brushed onto sizzling lamb skewers, drawing a snaking line of eager customers. At Shaanxi association stall, chefs tried Tianfu rapeseed oil to bake Roujiamo, praised by diners as a 'soulful carb bomb'. At Hunan association stall, chefs used Tianfu rapeseed oil to prepare the special topping for Changde rice noodles, delighting noodle lovers with its fragrant and refreshing taste. During the event, procurement managers from local Hong Kong catering groups and buyers from high-end supermarkets were drawn by the aroma. "The fragrance of Tianfu Rapoil is unique. After testing it in cooking, we noticed a significant improvement in the dishes' flavor," said a procurement representative from a well-known chain restaurant, who expressed immediate interest in establishing a stable supply channel after learning about the oil's production process and quality standards. The flood of partnership inquiries reflects the robust strength of Sichuan's rapeseed industry. As the province with the largest rapeseed cultivation area and the highest rapeseed oil consumption in China, Sichuan has in recent years taken the Tianfu Rapoil initiative as a starting point to drive the upgrading of the entire industrial chain, and enabled Tianfu Rapoil to stand out in the domestic edible oil sector, winning the 'China Grain and Oil Influential Public Brand' award for five consecutive years, with a brand value exceeding 10 billion yuan.
